StemCells Therapy » Stem Cell Therapy

Ivo Petrov, MD [Combined CCSVI

admin — Thu, 09 Feb 2012 04:07:47 +0000

www.youtube.com/watch?v=97AHSjRSvng

02-02-2012 09:26 CCSVI Symposium 2011 – Second Annual Meeting Crowne Plaza Hotel Times Square, Manhattan New York, NY July 15-17, 2011 www.ccsvicare.com Combined CCSVI and Stem Cell Treatments Ivo Petrov, MD Cardiology Department Chief Tokuda Hospital Sofia, Bulgaria [39 out of 46 videos]

Read more here:
Ivo Petrov, MD [Combined CCSVI

L. Grozdinski, MD [Stem Cell Therapy | CCSVI Symposium 2011 - 38 of 46] – Video

Stronger Health — Wed, 08 Feb 2012 16:15:31 +0000

www.youtube.com/watch?v=T9dfv3dWrWU

02-02-2012 08:37 CCSVI Symposium 2011 – Second Annual Meeting Crowne Plaza Hotel Times Square, Manhattan New York, NY July 15-17, 2011 www.ccsvicare.com Stem Cell Therapy L. Grozdinski, MD Angiology Sector Chief Tokuda Hospital Sofia, Bulgaria [38 out of 46 videos]

Stem Cell Treatment Paraplegic – Video

Anjali — Tue, 07 Feb 2012 22:51:32 +0000

www.youtube.com/watch?v=gC7e3pgtbKI

31-01-2012 21:38 www.StemCellTreatment.org Jaime Chiriboga was an active adult and ended up in a motorcycle accident and left a quadriplegic. Before receiving stem cell treatment he could not move his limbs. After his stem cell therapy he was able to move his limbs and got back almost 100% sensitivity in his body! We are very happy with the results and even more important Jaime is happy with his results! Please look at our website for more information!

Stem Cell Therapy for Type 1 Diabetes (UCSD, PDRC) – Video

haimb — Tue, 07 Feb 2012 03:13:39 +0000

www.youtube.com/watch?v=ZniSKi5g54E

20-01-2012 16:12 A conversation Dr. CC King, Ph.D., Associate Research Scientist at the UC, San Diego Pediatric Diabetes Research Center, about his work on stem cell therapy for type 1 (and type 2) diabetes.

See original here:
Stem Cell Therapy for Type 1 Diabetes (UCSD, PDRC) – Video

Suzanne Somers Uses Stem Cell Therapy for Breast Reconstruction

raymumme — Tue, 07 Feb 2012 03:13:38 +0000

Suzanne Somers, a breast cancer survivor who’s become known for her controversial advice against chemotherapy, has done something that other women can truly find hope in. She turned to stem-cell techniques to successfully reconstruct her breasts.

The rest is here:
Suzanne Somers Uses Stem Cell Therapy for Breast Reconstruction

Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid …

raymumme — Tue, 07 Feb 2012 03:13:37 +0000

SYDNEY, AUSTRALIA and SAN DIEGO, CA–(Marketwire -02/06/12)- Benitec Biopharma (ASX: BLT.AX – News) and Medistem (Pinksheets: MEDS.PK – News) announced today the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma's patented gene silencing technology applied to stem cell-derived immune system cells called dendritic cells. The studies, which were led by Dr. Wei-Ping Min of the University of Western Ontario, were published in the “Journal of Translational Medicine” on the 31st January 2012(1). Benitec Biopharma's CEO Dr Peter French and Medistem's scientist Dr Rosalia De Nochea Champion were co-authors on the paper.

“In 2003, Dr Wei-Ping Min's group, together with Medistem's CEO Dr Thomas Ichim, were the first to apply the technology of RNA Interference to the immune system, by silencing the autoimmune disease-associated gene IL-12p35(2),” said Dr. Peter French. “In the current paper, Dr. Min expanded these studies to a disease-relevant model, and using stem cell-derived dendritic cells was capable of developing promising preclinical data relevant to rheumatoid arthritis.”

By specifically “silencing” various genes, Benitec Biopharma's ddRNAi technology is capable of modulating stem cells outside of the body, in order to endow them with new desired therapeutic activities. The first clinical study which combined stem cell therapy with Benitec Biopharma's ddRNAi technology was in a trial of AIDS-related lymphoma patients, the results of which were published in 2010 and showed the safety and feasibility of the approach(3).

In the current paper, ddRNAi was used to generate dendritic cells that acted as a “tolerogenic vaccine,” which specifically blocked the pathological immune response in rheumatoid arthritis, without blocking healthy immune responses. It is contemplated that by blocking pathological immunity, ddRNAi-modified stem cell-based therapies, such as those being developed by Medistem, could provide novel treatment and curative approaches to tissue that has been damaged. In the case of rheumatoid arthritis the tissue would be cartilage and synovium.

“Medistem is the first company to take a stem cell from discovery to clinical trials in the short span of four years,” said Dr. Weiping Min. “This is a unique example of merging basic research, as performed in my laboratory with the translational expertise of Dr. Ichim's company.”

Medistem has previously published work in the area of rheumatoid arthritis, however the company's main efforts are currently focused on heart failure, for which it has started the RECOVER-ERC 60 patient double blind, dose escalating, placebo controlled trial using its Endometrial Regenerative Cell (ERC) universal donor stem cell. The company also has a critical limb ischemia trial recently approved by the FDA.

“In our opinion the Benitec Biopharma technology platform is the only means of inducing the stable expression of gene silencing in a stem cell,” said Dr. Ichim, CEO of Medistem. “Given that Benitec Biopharma has pioneered ddRNAi for human therapy, and has been involved in applying it to stem cell manipulation, we are eager to continue our collaborations and finding means of leveraging the unique properties of the ERCs with the transformational technology of ddRNAi to develop novel cell therapies for a range of chronic life-threatening human diseases.”

“Benitec Biopharma and Medistem are in discussions as to how to advance this work both in rheumatoid arthritis and in a range of other disease states that would lend themselves to such a novel combination therapy,” Dr. French added.

About Medistem
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia and heart failure. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf.

Cautionary Statement This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

About Benitec Biopharma

Benitec Biopharma Ltd is developing novel treatments for chronic and life-threatening conditions based on targeted gene-silencing activity using a transformational technology: DNA-directed RNA interference (ddRNAi) — sometimes called expressed RNAi. The technology's potential to address unmet medical needs and to cure disease results from its demonstrated ability to permanently silence genes which cause the condition. Importantly, this technology's target gene and related gene pathways will rarely have presented as a therapeutic avenue for research for the traditional small molecule agents, currently accounting for the majority of today's pharmaceutical products.

Benitec now either owns or exclusively licenses from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Founded in 1997 and trading publicly since 2001, Benitec Biopharma is listed on the Australian Securities Exchange (ASX) under the symbol “BLT.” Benitec aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In addition to its focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, Benitec Biopharma is pursuing programs with licensees.

References
(1) Li, R et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. “Journal of Translational Medicine” 2012, 10:19 doi:10.1186/1479-5876-10-19.
(2) Hill JA et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. “The Journal of Immunology,” 2003, 171: 691-696.
(3) DiGiusto DL et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-Related Lymphoma. “Science Translational Medicine,” 2(36): 36ra43.

Go here to see the original:
Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid …

Macular Damaged Vision Improved with Stem Cells

admin — Mon, 06 Feb 2012 15:32:49 +0000

Research using stem cells continues to be a controversial issue. But controversial or not, stem cell therapy use continues and new developments using the therapy to reverse vision loss are reported regularly. Keeping up with new improvements for reversal of vision loss for a person dealing with a vision issue is important. The idea of regaining vision offers hope to a person who lives with a vision impairment or blindness.

Researchers have reported vision loss improvement from a study using stem cells. Two women with different types of macular degeneration were treated with stem cell therapy. The first subject was a woman aged 70 with the dry form of aged related macular degeneration. The second subject was a woman aged 50 with Stargardt?s Macular Dystrophy.

The subjects were treated using 50,000 stem cells that were injected into one eye of each patient. The subjects were treated with eye therapy and followed for the next four months. During the four month time patients received eye therapy and eye exams. The vision of the first subject was improved by ten letters on a macular degeneration eye chart. The second subject ability to see movement improved and patient was able to see and count fingers correctly during hand movement tests. Researchers reported patients showed no signs of rejection or other difficulties during the stem cell trial.

What is macular degeneration?
The macular is the central part of the eye?s retinal nerve and is responsible for clarity and detail of central vision. Macular degeneration essentially, is the blocking of vision from debris in the eye or collection of fluid from leakage of abnormal growth of the blood vessels around the central part of the eye.

What are the different types of macular degeneration?
The disease is classified as wet or dry macular degeneration. The Dry form of the disease occurs when central vision damaged occurs from debris called drusen. Drusen shows up as yellow spots in the eyes. The drusen is thought to be material from deteriorating tissue.

Wet macular degeneration occurs when new blood vessels abnormally develop under the retina. The blood vessels begin to leak blood and fluid that collects around the macular causing damage and vision loss.

What are the risk factors?
1. Senior citizens Ages 60 and above
2. Smokers
3. Obesity
4. Race – White females have the highest number of cases

What treatments are available?
1. Wet Macular Degeneration
a. Drug injections
b. Laser surgery
c. Photodynamic therapy

2. Dry macular degeneration
a. Vitamins containing high levels of specific types of antioxidants
b. Balanced diet containing dark green leafy vegetables
c. Exercise

What are the symptoms?
1. The person may experience items such as; blurriness, squiggle or wavy lines and blind spots.
2. The faces of people seem wavy.
3. Doorways look crooked.
4. Objects look closer or farther away than normal

Medical research offers a visually disabled individual the hope of regaining vision. Staying informed and up to date on medical breakthroughs should be on the list of things to do for the visually disabled.

More:
Macular Damaged Vision Improved with Stem Cells

Clinic licensed by controversial stem cell treatment group

admin — Mon, 06 Feb 2012 13:26:42 +0000

Doctors say they are “licensed and trained” to perform a stem cell treatment pioneered by a group being sued by the Justice Dept. and FDA.

See original here:
Clinic licensed by controversial stem cell treatment group

From the Avro disappointment to the gift of stem-cell research

haimb — Mon, 06 Feb 2012 13:26:41 +0000

On Monday, former Avro Arrow engineer Owen Boris' family is announcing a $30M donation in his name to McMaster University for human stem-cell therapy research

Read more from the original source:
From the Avro disappointment to the gift of stem-cell research

$30 million donation from Boris family will help McMaster turn stem cell research into therapy

raymumme — Mon, 06 Feb 2012 10:54:23 +0000

McMaster University is on its way to moving stem cell research “from the bench to the bedside” thanks to a $30 million boost from a local family.

The Marta and Owen Boris Foundation made the large donation to establish a human stem cell therapy centre and a unique clinic for patients with complex health conditions.

Owen, the founder of Mountain Cablevision, was in talks with McMaster about investing in their work before he died last April. His children and wife contacted the university a month later and carried out his vision, firming up their commitment last November.

The Boris Family Centre in Human Stem Cell Therapies will be developed as part of the McMaster Stem Cell and Cancer Research Institute using $24 million of the funds.

“It’s getting over that chasm from the bench to the bedside that this (donation) is going to allow us to do,” the institute’s scientific director Dr. Mick Bhatia said.

The centre will give scientists the resources to focus on converting McMaster’s breakthroughs — such as the ability to make blood or types of neural cells with stem cells — into clinical applications through investigative trials, Bhatia said.

“In the absence of this donation, I think we would not be in the position to move our discoveries forward,” he said. “This is a huge leg-up. I’m hoping what it’s really going to do is have a ripple effect to change the way McMaster views translating basic science.”

They plan on developing human stem cell therapies targeting leukemia and possibly neural diseases such as Alzheimer’s and Parkinson’s, said Dr. John Kelton, dean and vice-president of the faculty of health sciences.

The remaining $6 million will go toward building a clinic in partnership with Hamilton Health Sciences (HHS) where patients with complex health issues can see specialists and undergo tests in one visit.

This was a result of his parents’ frustrating experiences in recent years with co-ordinating specialists and getting diagnostic testing done in Canada, said Owen’s son, Les Boris.

They ended up going to Mayo Clinic in Rochester, Minn., where they had a case manager who co-ordinated their appointments with specialists and made sure testing was done in-house, he said. “They like the idea of a one-stop shop … (My father) said: ‘This is the kind of model we need here in this country.’”

Kelton said the medical clinic, which will be built in the university’s medical centre, will look for rapid turnaround times and avoid duplications of lab tests. McMaster and HHS will also evaluate the clinic’s success and keep an electronic medical record that patients could access, he said.

Kelton and Owen met three years ago and had their last meeting about the projects three days before the philanthropist died.

Owen had worked on the Avro Arrow and was frustrated with Canada’s lost opportunity of making jet planes for the world, Kelton said.

“He said, ‘Tell me about some opportunities (that) – if we invested in it – could make Hamilton and McMaster world-class. What are some of the areas like an Avro Arrow?’”

The funds for the human stem cell therapy centre will go toward hiring a research chair in blood stem cells and a research chair in neural stems cells, setting up several fellowships and technician positions, and building the facility.

Bhatia says they hope to bring in new scientists and fellows by the early summer.

The Boris family previously donated $6 million to addiction research at St. Joseph’s Healthcare for its new mental health hospital being built on the Mountain and another $5 million for the da Vinci SI Surgical Robotic System.

“We’re very appreciative that we’re in a position to be doing something for the community,” Les said. “And it was the community that put us in the position to do this.

dawong@thespec.com

905-526-2468 | @WongatTheSpec

Originally posted here:
$30 million donation from Boris family will help McMaster turn stem cell research into therapy

Strategic Analysis of the European Stem Cell Research Tools Market

admin — Mon, 06 Feb 2012 10:54:22 +0000

NEW YORK, Feb. 6, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Strategic Analysis of the European Stem Cell Research Tools Market

http://www.reportlinker.com/p0769016/Strategic-Analysis-of-the-European-Stem-Cell-Research-Tools-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

The primary objective of this study is to measure brand perceptions of tools and technologies currently at the forefront of stem cell research: bio-imaging and microscopy, cell biology tools, immunochemicals, molecular biology tools, and protein biochemistry tools. The study also looks into the usage pattern of these tools. An extensive end-user survey was conducted with 25 laboratories to assess the requirement and usage of tools. Insightful review of key industry drivers, restraints and challenges have been discussed. Leading market players and the prevailing competitive landscape for each of the segments have been discussed.

Table of ContentsExecutive Summary 10-19

Executive Summary 11-13

Market Engineering Measurements 14

Scope & Objective 15

Technologies Employed for Stem Cell Research 16

Stem Cell Research Protocol 17

CEO's Perspective 18

Exchange Rates 19

Market Overview 19

Market Overview – Definitions 20-24

Market Overview 25-26

Market Overview – Segmentation 27

European Stem Cell Research End User Trends 28

Stem Cell Research Workflow 29

Purpose of Research and Profile of Respondents 30

Stem Cells and Tools Usage Trends 31-33

Tools and Equipment Budget for Stem cell research Tools 34

Market Outlook 35

Market Age 36

Funding for Stem Cell Program 37-39

External Challenges: Drivers and Restraints 40

Industry Challenges 41-45

Drivers & Restraints 46

Key Market Participants 52

Product Line Analysis 59

Forecasts and Trends -Total Stem Cell Research Tools Market 70

Forecast Assumptions 72

Revenue Forecasts 73-74

Bio Imaging Tools In Vivo and In Vitro Segment Breakdown 75

Revenue Forecasts 77-78

Market Share Analysis 79

Cell Biology, Protein Biochemistry, and Immunochemical Tools Segment Breakdown 80

Revenue Forecasts 82-83

Market Share Analysis 84

Molecular Biology Tools Segment Breakdown 85

Revenue Forecasts 87-88

Market Share Analysis 89

Demand Analysis 90

Bioimaging Tools In Vivo and In Vitro 92

Cell Biology Tools 93

Demand Analysis Molecular Biology Tools 94

Protein Biochemistry Tools 95

Immunochemical Tools 96

European Stem Cell Research Centers 97-99

SWOT Analysis 101-102

Strategic Recommendations and Conclusions 103-106

The Last Word 107

Appendix 110

List of Figures

Total Stem Cell Research Tools Market: Market Overview, Europe, 2010 25Total Stem Cell Research Tools Market: Tools Usage Trends, Europe, 2010 32-33Total Stem Cell Research Tools Market: Market Outlook, Europe, 2010 35Total Stem Cell Research Tools Market: R&D Programs Funded, Europe, 2006–2013 37Total Stem Cell Research Tools Market: Bioimaging Tools In Vivo and In Vitro End User Analysis, Europe, 2010 92Total Stem Cell Research Tools Market: Cell Biology Tools End User Analysis, Europe, 2010 93Total Stem Cell Research Tools Market: Molecular Biology Tools End User Analysis, Europe, 2010 94Total Stem Cell Research Tools Market: Protein Biochemistry Tools End User Analysis, Europe, 2010 95Total Stem Cell Research Tools Market: Immunochemical Tools End User Analysis, Europe, 2010 96

List of Charts

Percent Revenue Breakdown Total Stem Cell Research Tools Market: Europe, 2010 27

Percent Revenue Breakdown Total Stem Cell Research Tools Market: Europe, 2017 27

Total Stem Cell Research Tools Market: Purpose of Research and Profile of Respondents, Europe, 2010 30

Total Stem Cell Research Tools Market: General and Primary Focus on Stem Cell Research, Europe, 2010 31

Total Stem Cell Research Tools Market: Lab Budgets, Europe, 2010 34

Total Stem Cell Research Tools Market: Lab Budget Estimations, Europe, 2011 34

Total Stem Cell Research Tools Market: Segment Life Cycle Analysis, Europe, 2010 36

Total Stem Cell Research Tools Market: Industry Challenges, Europe, 2011–2017 41

Total Stem Cell Research Tools Market: Drivers and Restraints, Europe, 2010 46

Total Stem Cell Research Tools Market: Product Line Analysis, Europe, 2010 59-67

Market Overview Total Stem Cell Research Tools: Europe, 2010 71

Total Stem Cell Research Tools: Revenue Forecast, Europe, 2010–2017 73

Market Overview Bioimaging In Vivo and In Vitro Market: Europe, 2010 76

Bioimaging Tools In Vivo and In Vitro Market: Revenue Forecasts, Europe, 2010–2017 77

Bioimaging In Vivo and In Vitro Market: Market Share Analysis, Europe, 2010 79

Market Overview Cell Biology, Protein Biochemistry, and Immunochemical Tools Market: Europe, 2010 81

Cell biology, Protein Biochemistry, and Immunochemical Tools Market Revenue Forecasts, Europe, 2010–2017 82

Cell Biology, Protein Biochemistry, and Molecular Biology Tools Market: Market Share Analysis, Europe, 2010 84

Market Overview Molecular Biology Tools Market: Europe, 2010 86

Molecular Biology Tools Market: Revenue Forecasts, Europe, 2010–2017 87

Molecular Biology Tools Market: Market Share Analysis, Europe, 2010 89

Total Stem Cell Research Tools Market: Research Centers and Universities, Europe, 2010 98-100

Total Stem Cell Research Tools Market: SWOT Analysis, Europe, 2010 102

To order this report:Biological Therapy Industry: Strategic Analysis of the European Stem Cell Research Tools Market

Market Research Report

Check our

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Read the rest here:
Strategic Analysis of the European Stem Cell Research Tools Market

PRWEB: Absorption Systems Expands In Vivo Drug and Medical Device Testing Capabilities

admin — Sun, 05 Feb 2012 16:56:02 +0000

Preclinical contract research organization renovates facility, adding state-of-the-art technology and upgrading ocular testing services.

Exton, PA (PRWEB) January 31, 2012

Absorption Systems announces the latest in a series of milestones in the continuing expansion of its AAALAC-accredited and GLP-compliant facility in San Diego, CA. The facility is undergoing extensive renovations to upgrade and expand the company’s in vivo testing capabilities for drugs and medical devices, including the construction of a dedicated ocular testing laboratory with state-of-the-art equipment, including a Heidelberg Spectralis® optical coherence tomography (OCT) unit. This instrument produces detailed digital images of the retina, enabling precise monitoring of the efficacy and toxicity of drugs and medical devices. Absorption Systems’ San Diego facility, in the midst of a major expansion of staff, equipment, and capabilities in the specialized area of preclinical ocular drug and device testing, continues to see significant growth year-over-year early in 2012.

Glenwood Gum, M.S., Ph.D., who joined Absorption Systems in 2011 as Associate Director, Preclinical Studies, commented, “This OCT technology gives a huge boost to our ocular testing capabilities, which will immediately benefit our rapidly expanding client base.” Dr. Gum is an expert in preclinical ocular studies, having developed or co-developed many of the preclinical models of glaucoma, age-related macular degeneration (AMD), retinoblastoma, uveitis, and diabetic retinopathy that are used all over the world for drug testing. His expertise, along with dedicated staff and the addition of state-of-the-art equipment and facilities, are key to Absorption Systems’ strategy to aggressively pursue new business opportunities in the preclinical ocular testing arena.

Dr. Gum will be a featured speaker on Preclinical Glaucoma and CNV Models at the 4th Ocular Diseases and Drug Discovery conference in Las Vegas, NV February 27-28, 2012.

Patrick Dentinger, President and CEO of Absorption Systems, said, “For Absorption Systems, being a market leader in whatever endeavor we pursue is a cornerstone of our business philosophy. This requires scientific expertise, state-of-the-art equipment and facilities, and access to emerging technologies. These factors, combined with Absorption Systems’ customer-centric approach, make our commitment to being a top-tier ocular service provider a reality in 2012.”

Absorption Systems’ preclinical ocular test portfolio includes in vivo ocular pharmacokinetics, efficacy, and safety in multiple species, as well as in vitro ocular permeability and metabolism. For example, the human corneal orb is a unique in vitro permeability model available as a service platform only through Absorption Systems. The corneal orb, cultured from human pluripotent stem cells, was developed by Lifeline Cell Technology, Inc., a wholly-owned subsidiary of International Stem Cell Corporation, and has been validated by Absorption Systems as an in vitro corneal permeability test system.

About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems’ commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company’s comprehensive contract services and applied research programs, please visit http://www.absorption.com.

SOURCE: http://www.prweb.com/releases/2012/1/prweb9153045.htm

Source:
http://intlstemcell.blogspot.com/feeds/posts/default

Cloned brain cells could help MS, Parkinsons, depression patients

admin — Sun, 05 Feb 2012 16:56:01 +0000

From the birthplace of Dolly the sheep comes another advancement in cloning, as scientists at Scotland’s University of Edinburgh have reportedly created brain tissue from patients suffering from mental illnesses.

According to NewsCore reports, researchers at the university’s Centre for Regenerative Medicine (CRM) have developed a method of taking a patient’s skin sample, turning it into stem cells, and then directing them to grow into brain cells. They then study those man-made brain cells hoping to learn more about patients suffering from ailments such as bipolar depression and schizophrenia.

“A patient’s neurons can tell us a great deal about the psychological conditions that affect them, but you cannot stick a needle in someone’s brain and take out its cells,” CRM Director Charles ffrench-Constant told Robin McKie of The Guardian on Saturday…. [Read More]

Source:
http://feeds.rapidfeeds.com/3071/

Skin transformed into brain cells

admin — Sun, 05 Feb 2012 16:55:58 +0000

Skin cells have been converted directly into cells which develop into the main components of the brain, by researchers studying mice in California.

The experiment, reported in Proceedings of the National Academy of Sciences, skipped the middle "stem cell" stage in the process.

The researchers said they were "thrilled" at the potential medical uses.

Far more tests are needed before the technique could be used on human skin…. [Read More]

Source:
http://feeds.rapidfeeds.com/3071/

Chaos in the cell’s command center

admin — Sun, 05 Feb 2012 16:55:54 +0000

Researchers have determined the critical role one enzyme, lysine-specific demethylase 1 (LSD1), plays as mouse embryonic stem cells (ESCs) differentiate. This research may provide targets for developing drugs to push cells with dysfunctional gene expression programs back to a more normal, healthier state.Source:
http://www.sciencedaily.com/rss/health_medicine/stem_cells.xml

Skin cells turned into neural precusors, bypassing stem-cell stage

admin — Sun, 05 Feb 2012 16:55:53 +0000

Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons.Source:
http://www.sciencedaily.com/rss/health_medicine/stem_cells.xml

Encouraging results with stem cell transplant for brain injury

admin — Sun, 05 Feb 2012 16:55:53 +0000

Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery.Source:
http://www.sciencedaily.com/rss/health_medicine/stem_cells.xml

Stem cells could drive hepatitis research forward

admin — Sun, 05 Feb 2012 16:55:53 +0000

Researchers have produced liver-like cells from induced pluripotent stem cells. By creating liver-like cells, scientists can study why people respond differently to Hepatitis C.Source:
http://www.sciencedaily.com/rss/health_medicine/stem_cells.xml

Need muscle for a tough spot? Turn to fat stem cells

admin — Sun, 05 Feb 2012 16:55:52 +0000

Stem cells derived from fat have a surprising trick up their sleeves: Encouraged to develop on a stiff surface, they undergo a remarkable transformation toward becoming mature muscle cells. The new cells remain intact and fused together even when transferred to an extremely stiff, bone-like surface, which has bioengineers intrigued. These cells, they suggest, could hint at new therapeutic possibilities for muscular dystrophy.Source:
http://www.sciencedaily.com/rss/health_medicine/stem_cells.xml

Analysis looks at cost effectiveness of simultaneously confronting several diseases

admin — Sun, 05 Feb 2012 16:55:51 +0000

The great paradox of global health efforts is that regions of the world most plagued by poverty, poor infrastructure and rampant disease are often the most difficult to support. Now, scientists have demonstrated that confronting several diseases at once can make the most of thinly-stretched donor dollars and national health care budgets, to help to save lives.Source:
http://www.news-medical.net/syndication.axd